Mediclinic International plc Director/PDMR Shareholding (0590H)

TIDMMDC

RNS Number : 0590H

Mediclinic International plc

02 June 2017

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

2 June 2017

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Awards under the Company's Short-Term Incentive Scheme

On 1 June 2017, awards over ordinary shares in Mediclinic (the "Shares") were granted to the following Directors and other persons discharging managerial responsibilities ("PDMRs") under the rules of the Company's Short-Term Incentive ("STI") Scheme, which was approved by shareholders in December 2015:

 
 Name               Director/    Number of Shares awarded 
                     PDMR         under the Short Term 
                                  Incentive Scheme 
-----------------  -----------  ------------------------- 
 Danie Meintjes     Director     27,187 
-----------------  -----------  ------------------------- 
 Jurgens Myburgh    Director     10,815 
-----------------  -----------  ------------------------- 
 

Nil consideration per share was paid for the grant of the awards. The vesting of an award is subject to employment conditions; no further performance conditions apply.

The following notification made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation relates to the Company's STI Scheme.

 
 1.   Details of PDMR / person closely associated 
       with them ("PCA") 
---  ------------------------------------------------------------- 
 a)   Name                   Daniël Petrus Meintjes 
---  ---------------------  -------------------------------------- 
 2.   Reason for the notification 
---  ------------------------------------------------------------- 
 a)   Position               Chief Executive Officer of the 
       / status               Company 
---  ---------------------  -------------------------------------- 
 b)   Initial notification   Initial Notification 
       / amendment 
---  ---------------------  -------------------------------------- 
 3.   Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ------------------------------------------------------------- 
 a)   Name                   Mediclinic International plc 
---  ---------------------  -------------------------------------- 
 b)   LEI                    2138002S5BSBIZTD5I60 
---  ---------------------  -------------------------------------- 
 4.   Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ------------------------------------------------------------- 
 a)   Description            Ordinary Shares 
       of the financial 
       instrument             GB00B8HX8Z88 
       Identification 
       Code 
---  ---------------------  -------------------------------------- 
 b)   Nature of              Award over ordinary shares in 
       the transaction        Mediclinic International plc granted 
                              under the Company's Short Term 
                              Incentive Scheme 
---  ---------------------  -------------------------------------- 
 c)   Price(s)                 Price(s)    Volume(s) 
       and volume(s)           ----------  ---------- 
                                Nil cost    27,187 
                               ----------  ---------- 
---  ---------------------  -------------------------------------- 
 d)   Aggregated 
       information 
       Aggregated 
       volume                  27,187 
       Price 
                               ZAR0.00 
---  ---------------------  -------------------------------------- 
 e)   Date of the            1 June 2017 
       transaction 
---  ---------------------  -------------------------------------- 
 f)   Place of               Johannesburg Stock Exchange 
       the transaction 
---  ---------------------  -------------------------------------- 
 
 
 1.   Details of PDMR / person closely associated 
       with them ("PCA") 
---  ------------------------------------------------------------- 
 a)   Name                   Petrus Jurgens Myburgh 
---  ---------------------  -------------------------------------- 
 2.   Reason for the notification 
---  ------------------------------------------------------------- 
 a)   Position               Chief Financial Officer of the 
       / status               Company 
---  ---------------------  -------------------------------------- 
 b)   Initial notification   Initial Notification 
       / amendment 
---  ---------------------  -------------------------------------- 
 3.   Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ------------------------------------------------------------- 
 a)   Name                   Mediclinic International plc 
---  ---------------------  -------------------------------------- 
 b)   LEI                    2138002S5BSBIZTD5I60 
---  ---------------------  -------------------------------------- 
 4.   Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ------------------------------------------------------------- 
 a)   Description            Ordinary Shares 
       of the financial 
       instrument             GB00B8HX8Z88 
       Identification 
       Code 
---  ---------------------  -------------------------------------- 
 b)   Nature of              Award over ordinary shares in 
       the transaction        Mediclinic International plc granted 
                              under the Company's Short Term 
                              Incentive Scheme 
---  ---------------------  -------------------------------------- 
 c)   Price(s)                 Price(s)    Volume(s) 
       and volume(s)           ----------  ---------- 
                                Nil cost    10,815 
                               ----------  ---------- 
---  ---------------------  -------------------------------------- 
 d)   Aggregated 
       information 
       Aggregated 
       volume                  10,815 
       Price 
                               ZAR0.00 
---  ---------------------  -------------------------------------- 
 e)   Date of the            1 June 2017 
       transaction 
---  ---------------------  -------------------------------------- 
 f)   Place of               Johannesburg Stock Exchange 
       the transaction 
---  ---------------------  -------------------------------------- 
 

About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1 600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700 inpatient beds in the United Arab Emirates.

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Capita Company Secretarial Services Limited

Victoria Dalby

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Brett Pollard/Debbie Scott (UK)

[phone]

Frank Ford (South Africa)

[phone]

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBSGDLXDGBGRD

(END) Dow Jones Newswires

June 02, 2017 11:00 ET (15:00 GMT)